Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Adhera Therapeutics, Inc.t1502705_ex99-1.htm
EX-99.2 - EXHIBIT 99.2 - Adhera Therapeutics, Inc.t1502705_ex99-2.htm
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):   November 16, 2015

 

Marina Biotech, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   000-13789   11-2658569
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
         
P.O. Box 1559 , Bothell, WA       98041
(Address of principal executive offices)       (Zip Code)

 

Registrant’s telephone number, including area code:   425-892-4322

 

N/A

 

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
   
   

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 16, 2015, Marina Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2015. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 8.01 Other Events.

 

On November 17, 2015, the Company issued a press release announcing that it received a milestone payment, in the amount of $200,000, from its licensee, MiNA Therapeutics Limited, a privately-held biotechnology company pioneering short activating RNA as therapeutic agents for the treatment of human diseases. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
     
99.1   Press release of Marina Biotech, Inc. dated November 16, 2015.
     
99.2   Press release of Marina Biotech, Inc. dated November 17, 2015.

 

   
   

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Marina Biotech, Inc.
     
November 17, 2015 By: /s/ J. Michael French
  Name:  J. Michael French
  Title: Chief Executive Officer

 

   
   

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press release of Marina Biotech, Inc. dated November 16, 2015.
     
99.2   Press release of Marina Biotech, Inc. dated November 17, 2015.